Back to results
RecruitingN/A

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)

NCT05722795

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Barbro Linderholm

Gothenburg, Sweden

Contact

Barbro K Linderholm, MD, PhD

+46706045422barbro.linderholm@oncology.gu.se
View on ClinicalTrials.gov
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) — TrialFind